Mitigating unintentional effects of pharmaceutical human serum albumin preparations in therapeutic cell culture

Human Serum Albumin (HSA) has historically been used in cell culture to support mammalian cell growth. Today’s advanced therapy companies regularly depend on HSA media supplementation to help expand targeted immunotherapeutic cell lines. Albumin is known to carry many important substances including lipids, amino acids, hormones, peptides, metals, and other undefined low molecular weight molecules.1

Akron Biotech appoints new Scientific Advisory Board, further expanding its cell and gene therapy industry expertise

Boca Raton, FL, US, April 7, 2021 – Akron Biotech, a leading developer and manufacturer of cGMP-compliant ancillary materials for cell and gene therapy development and commercialization, today announces the appointment of a new Scientific Advisory Board. The board is comprised of world-leading scientists and experts in the cell and gene therapy field. It will

Enhancing the safety of virus-inactivated ancillary materials through neutralizing antibodies

The discovery of antibodies in the late nineteenth century marks one of the most significant advancements in our understanding of the human immune system. It catalyzed over a century of rapidly evolving investigations and characterizations of the invisible biochemical mechanisms that keep us safe every day. This blossoming immunological understanding continues to progress alongside our

Going Green, the Akron Way

One small act can change the world, which is why we at Akron Biotech began our work with One Tree Planted in 2018. The mission behind One Tree Planted is simple: While the problems around climate change and deforestation are vast, planting a tree is something anyone can do. The non-profit is committed to planting

Reducing Variability in Cytokine Activity Reporting

Ensuring the quality and consistency of ancillary materials used in the manufacture of cell and gene therapies is critical to both controlling costs and ensuring the integrity of the therapeutic product. It is our responsibility as ancillary material manufacturers to reduce the variability that biomanufacturing presents. This is especially important when considering the manufacture of

Safety First: Methods of virus inactivation for increased safety of advanced therapies

Regulatory agencies around the world have been steadily increasing pressure on cell, gene, and tissue-engineered drug development companies to put safety first and find ways to control the inherent risks present in many of the raw materials used in the downstream processing of their advanced therapies. The industry has been largely transitioning away from animal-derived

Akron Biotech Signs Agreement with Synairgen plc to Supply Interferon-beta for COVID-19 Treatment

Akron Biotech Signs Agreement with Synairgen plc to Supply Interferon-beta for COVID-19 Treatment BOCA RATON, FL – October 19, 2020 – Akron Biotechnology today announced it has signed an agreement with Synairgen plc (LSE: SNG) for the provision of SNG001, Synairgen’s wholly-owned inhaled interferon beta (IFN-beta) therapeutic candidate for the treatment of COVID-19 patients. Akron

COVID-19 Response

Akron Biotech is committed to help defeat COVID-19 – Together we cure Coronavirus disease 2019 (COVID-19) is a pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Symptoms tend to appear 2-14 days after exposure to the virus and can range from mild to severe, with some patients requiring  hospitalization1. In response to this